Rationale: Studies in cultured endothelium implicate that lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) or Fcγ receptor II (CD32) contributes to the proatherogenic effects of C-reactive protein (CRP). However, the identity of the receptors linking to deleterious actions of CRP in vasomotor regulation remains unknown.
I nflammation-related cardiovascular disturbance is regarded as a pivotal event in the development of atherosclerosis. 1 C-reactive protein (CRP), a biomarker of inflammation and cardiovascular deterioration, is becoming an emerging risk factor for cardiovascular disease. The landmark Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study recently showed that statin therapy significantly reduced the CRP levels, along with the incidence of major cardiovascular events, in apparently healthy individuals with elevated CRP (≥2 µg/mL). 2, 3 Despite the lack of direct evidence for a causal link of CRP, accumulating findings suggest that CRP is actively involved in promoting adverse cardiovascular outcomes because of its proatherogenic effects on vascular cells. 4 In cell culture models, CRP, at relatively high pharmacological concentrations (25-100 µg/mL), has been shown to elevate reactive oxygen species generation from vascular cells 5, 6 and impair nitric oxide (NO) synthase (NOS) activity and NO production, 7, 8 as well as prostacyclin (PGI 2 ) release, 5 from endothelial cells. Extending the studies from a homogeneous cell type in culture, we recently demonstrated in intact coronary arterioles that CRP, at a clinically relevant concentration (7 µg/mL), impairs endothelium-dependent NO-mediated and PGI 2 -mediated dilations by reducing NO bioavailability 9 and inhibiting PGI 2 synthase activation, respectively. 10 The detrimental effect of CRP on vasodilator function depended on endothelial production of reduced form of nicotinamide dinucleotide phosphate (NAD[P]H) oxidase-derived superoxide 9
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Travis W. Hein,* Erion Qamirani,* Yi Ren, Xin Xu, Naris Thengchaisri, Lih Kuo and subsequent formation of peroxynitrite rather than inactivation of NOS or cyclooxygenase. 10 Several clinical studies have also demonstrated a strong correlation between diminished vascular reactivity 11, 12 and increased coronary microvascular resistance 13 in association with high levels of CRP (3-10 µg/mL). In addition, local production of CRP within the coronary circulation has been associated with impaired coronary endothelium-dependent vasodilation in patients with acute coronary syndrome. 14 Taken together, experimental and clinical findings support the notion of CRP as a mediator of vascular dysfunction in the microcirculation, the primary site for blood pressure and flow control.
Despite the overwhelming evidence from both animal and human studies assigning a pathophysiological role to CRP, the identity of the receptor in intact blood vessels mediating deleterious actions of CRP has not been determined. Previous studies in cultured aortic endothelial cells have provided disparate results, implicating that CRP activates Fcγ receptor II (CD32) [15] [16] [17] or lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). 18, 19 Because LOX-1, a scavenger receptor, can bind to several pathogenic ligands and cause endothelial dysfunction similar to that induced by CRP, 20 we propose that CRP inhibits endothelium-dependent vasodilation via generation of oxidative stress by activating LOX-1 in intact arterioles. To test this hypothesis without the confounding influences from hemodynamic and humoral factors associated with in vivo preparations, porcine coronary arterioles were isolated and pressurized for vasomotor assessment and biochemical/immunohistochemical studies.
Methods
Please see the Online Data Supplement for an expanded Methods section.
Functional Assessment of Isolated Coronary Arterioles
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (Publication No. 85-23, revised 1996). All animal procedures were approved by the Scott & White Institutional Animal Care and Use Committee and have been described previously. 21 Pigs were anesthetized with 2% to 4% isoflurane, and the heart was quickly excised. Individual subepicardial arterioles (40-100 µm in internal diameter in situ) were dissected from the surrounding cardiac tissue for in vitro study. Vessels were cannulated and pressurized to 60 cm-H 2 O intraluminal pressure without flow. 21 The human recombinant CRP and high purity serum CRP (Calbiochem) used in the following protocols were prepared as reported previously. 9 After coronary arterioles developed stable basal tone, the vasodilator function was assessed by challenging the vessels with an endothelium-dependent NO-mediated agonist serotonin 22 before and after extraluminal incubation of vessels with NOS inhibitor N G -nitro-l-arginine methyl ester (10 µmol/L) or 60-minute intraluminal incubation with a clinically relevant concentration of CRP (7 µg/mL). 23 To confirm the activity of recombinant CRP, human serum-derived natural CRP (Calbiochem) was used. To verify the specific action of CRP, an anti-CRP monoclonal antibody 24 was used (clone CRP-8; Sigma; 35 µg/mL). The roles of LOX-1 and CD32 in mediating the CRP effect were examined in a separate group of vessels by determining dilation to serotonin before and after coadministration of CRP with an anti-LOX-1 antibody (5 µg/mL; Abcam) 25 or an anti-CD32 antibody (5 µg/mL; Santa Cruz Biotechnology). 26, 27 κ-Carrageenan (125 µg/mL), a LOX-1 antagonist, 25, 28 and catalase (1000 U/mL), 29, 30 the hydrogen peroxide scavenger, were administered to determine the role of LOX-1 and hydrogen peroxide, respectively, in the observed CRP effect. In another cohort of vessels, vasodilation to arachidonic acid (10 µmol/L), 10 an endothelium-dependent PGI 2 -mediated agonist, was examined before and after incubation with PGI 2 synthase inhibitor trans-2-phenyl cyclopropylamine (TPC; 100 µmol/L) 10 or after 60-minute intraluminal incubation with recombinant CRP (7 µg/mL) in the absence or presence of an anti-LOX-1 antibody (5 µg/ mL), TPC plus an anti-LOX-1 antibody, or an anti-CD32 antibody (5 µg/mL). In preliminary studies, dilations of coronary arterioles to serotonin and arachidonic acid were repeatable without any sign of tachyphylaxis (data not shown).
Diameter changes in response to vasodilator agonists were normalized to the maximal diameter change in response to 100 µmol/L sodium nitroprusside in EDTA (1 mmol/L)-Ca 2+ -free physiological saline solution and expressed as % maximal dilation. 31 Data are presented as mean±SEM. Statistical comparisons of vasomotor responses under different treatments were performed with 1-or 2-way ANOVA followed by the Bonferroni multiple range test, as appropriate. Differences in resting diameter before and after pharmacological interventions were compared with paired Student's t-test. A value of P<0.05 was considered significant.
Detection of Superoxide
Real-time detection of superoxide production from isolated porcine coronary arterioles in the presence or absence of endothelium was conducted using dihydroethidium (DHE) with slight modification from a previous study. 32 Images were taken with a fluorescence microscope (Axiovert 200, Zeiss). The resulting images were quantitatively analyzed for DHE fluorescence intensity using ImageJ software (National Institutes of Health, Bethesda, MD) as described previously. 33 Data are presented as mean±SEM. Statistical comparisons of data were performed with 1-way ANOVA followed by the Bonferroni multiple range test. A value of P<0.05 was considered significant.
Immunohistochemical Detection of LOX-1 and CD32
Coronary arterioles were prepared for immunohistochemical analysis as described previously. 34 Sections (10-µm thick) were immunolabeled with anti-LOX-1 polyclonal antibody (1:150 dilution), anti-CD32 monoclonal antibody (1:100 dilution), anti-endothelial NOS (eNOS) monoclonal antibody (1:100 dilution), anti-CRP monoclonal antibody (1:100 dilution, costaining with anti-LOX-1), or anti-CRP polyclonal antibody (1:100 dilution, costaining with anti-CD32). The eNOS staining was used as a marker for endothelial layer localization. Images were observed using fluorescence microscopy as described previously. 34 
Cell Culture
Human coronary artery endothelial cells (HCAEC) were purchased from Genlantis. Cells at passage 3 or 4 were pretreated with anti-CD32 antibody (5 µg/mL), anti-LOX-1 antibody (5 µg/mL), or vehicle control (physiological saline solution) for 30 minutes, and then recombinant CRP (7 µg/mL) was added to the cells for 12 hours. After the 12-hour incubation, cells were sonicated, and the protein 
Immunoprecipitation and Western Blot Analysis
To determine whether CRP binds to LOX-1 and CD32 in intact vessels, isolated coronary arterioles were incubated with vehicle (physiological saline solution) or recombinant CRP (7 µg/mL) for 60 minutes. Protein isolated from each vessel sample was used for immunoprecipitation and Western blot analysis as described previously. 10 Because activation of CD32 by CRP has been shown in cultured cells to alter the expression of thrombogenic proteins such as plasminogen activator inhibitor-1 (PAI-1), 35 we assessed whether CRP influences PAI-1 protein expression in intact blood vessels. In this regard, coronary arterioles were isolated and incubated with vehicle, recombinant CRP (7 µg/mL), CRP plus anti-LOX-1 antibody (5 µg/ mL), or CRP plus anti-CD32 antibody (5 µg/mL) for 12 hours. The possible roles of both LOX-1 and CD32 activation in CRP-induced endothelial PAI-1 expression were also assessed in cultured HCAEC as described above. Protein isolated from each vessel and cell sample was used for Western blot analysis with an anti-PAI-1 monoclonal antibody (1:500; R&D Systems). Statistical comparisons of data were performed with 1-way ANOVA followed by the Bonferroni multiple range test. A value of P<0.05 was considered significant. Data are presented as mean±SEM.
Results

Role of LOX-1 in CRP-Induced Endothelial Dysfunction
All isolated coronary arterioles developed a similar level of basal tone, ≈61±1% of maximal passive diameter (87 µm; range, 57-118 µm). Serotonin dilated coronary arterioles in a concentration-dependent manner ( Figure 1 ), and this dilation was significantly reduced by N G -nitro-l-arginine methyl ester ( Figure 2A ). In another set of experiments, administration of recombinant CRP to the lumen of the vessel for 60 minutes did not alter basal diameter (control, 54±5 µm; CRP, 55±5 µm) but significantly attenuated the dilation to serotonin ( Figure  1 ) in a comparable manner as that produced by N G -nitro-larginine methyl ester (Figure 2A ). In contrast, CRP did not affect endothelium-independent vasodilation to an NO donor sodium nitroprusside (Online Figure I) . The adverse effect of recombinant CRP was neutralized in the presence of an anti-CRP monoclonal antibody (Figure 2A ). In the presence of LOX-1 antagonist κ-carrageenan 19 or anti-LOX-1 antibody, the adverse effect of CRP on serotonin-induced vasodilation was also eliminated ( Figure 2B ). However, blocking CD32 with an anti-CD32 antibody had no influence on the inhibitory action of CRP ( Figure 2B ). Arachidonic acid (10 µmol/L) elicited a significant dilation of coronary arterioles, and this dilation was nearly abolished by PGI 2 synthase inhibitor TPC A, Coronary arteriolar dilation to serotonin was examined before and after extraluminal incubation with NO synthase inhibitor N G -nitro-l-arginine methyl ester (L-NAME; n=5) or intraluminal incubation with 7 µg/mL CRP in the absence (n=7) and presence of anti-CRP antibody (35 µg/mL; n=4). B, Vasodilation to serotonin was examined before and after incubation with 7 µg/mL CRP in the absence (n=7) and presence of LOX-1 antagonist κ-carrageenan (125 µg/mL; n=5), anti-LOX-1 antibody (5 µg/mL; n=10), or anti-CD32 antibody (5 µg/mL; n=4). Diameter changes to serotonin were normalized to the maximal dilation in response to sodium nitroprusside (10 -4 mol/L). *P<0.05 vs control. Ab indicates antibody; and n, number of vessels (1 per animal).
( Figure 3 ). In a similar manner as TPC treatment, CRP significantly attenuated the arachidonic acid-induced vasodilator response. The inhibitory effect of CRP on vasodilation to arachidonic acid was sensitive to an anti-LOX-1 antibody but was unaffected by an anti-CD32 antibody (Figure 3 ). In addition, the arachidonic acid-induced vasodilation protected by the anti-LOX-1 antibody was sensitive to TPC (Figure 3 ), suggesting that the preserved vasodilator response was related to the ability of the coronary arterioles to produce PGI 2 .
Role of LOX-1 in CRP-Induced Superoxide Production
Because we previously showed that elevated superoxide production contributes to CRP-induced impairment of serotonin-induced vasodilation, 9 we determined whether LOX-1 activation influences superoxide levels in live, pressurized coronary arterioles. In the absence of CRP (ie, vehicle control), real-time DHE fluorescence revealed sparse levels of superoxide in the arteriolar wall ( Figure 4 ). However, intraluminal incubation of vessels with CRP (7 µg/mL; 60 minutes) markedly increased 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL)-sensitive superoxide levels about 3-fold, predominantly in the endothelial cells with longitudinal alignment of nuclear staining and sparse transverse nuclear staining of smooth muscle cells. In the presence of an anti-LOX-1 antibody but not an anti-CD32 antibody, the elevated superoxide level in the endothelium and smooth muscle was significantly reduced (Figure 4 ). In the absence of endothelium, both longitudinal and transverse DHE signals were negligible with ( Figure 4 ) or without (data not shown) CRP treatment. In these endothelium-denuded vessels, the vasodilation to serotonin (0.1 µmol/L) was abolished (control: 63±4% dilation versus denudation: 3±1% dilation; n=4), and the endotheliumindependent vasodilation to sodium nitroprusside (10 µmol/L) was unaltered (control: 85±6% dilation versus denudation: 80±9% dilation; n=4). In the presence of an effective concentration of catalase, 29,30 a scavenger of hydrogen peroxide, the inhibitory effect of CRP on vasodilation to serotonin remained (Online Figure II) .
Cellular Localization of LOX-1 and CD32 in Coronary Arterioles
Immunostaining results indicated that LOX-1 staining was primarily localized to the endothelial layer and was closely associated with eNOS signals ( Figure 5A ). After treating the vessels with CRP, this peptide was detected in the location highly expressed with LOX-1 ( Figure 5B ). CD32 was also expressed primarily in the endothelial layer of coronary arterioles and overlapped with eNOS and CRP ( Figure 5C and 5D) . Support for the binding of CRP with LOX-1 and CD32 was provided by Western blot data showing detection of CRP in immunoprecipitated LOX-1 or CD32 protein from coronary arterioles pretreated with CRP only ( Figure 6 ).
Roles of LOX-1 and CD32 in CRP-Induced Increase in PAI-1 Expression
The positive coimmunoprecipitation of CRP with both LOX-1 and CD32 suggests a close interaction of these receptors with CRP. Because CRP has been shown to promote PAI-1 expression via CD32 activation in cultured endothelial cells, we examined the roles of LOX-1 and CD32 in regulating the expression of PAI-1 in intact coronary arterioles. After 12-hour incubation of coronary arterioles with CRP, PAI-1 protein expression increased ≈3-fold (Figure 7) . The CRPinduced increase in PAI-1 expression was abolished by either an anti-LOX-1 or an anti-CD32 antibody (Figure 7 ). There was no greater inhibitory effect after combined treatment with both antibodies (n=2, data not shown). However, the ability of CRP to increase PAI-1 expression in cultured HCAEC was inhibited by an anti-CD32 antibody but was unaffected by an anti-LOX-1 antibody (Figure 8) . Notably, the specificity of the anti-LOX-1 and anti-CD32 antibodies for the cognate proteins was confirmed via immunoblots of control nontreated HCAEC (Online Figure IIIA) . In addition, the LOX-1 antibody detected the knockdown of LOX-1 protein expression by ≈75% in HCAEC after LOX-1 siRNA, but not scrambled siRNA, treatment. Both LOX-1 and scrambled siRNA had no effect on the actin protein expression (Online Figure IIIB) . These data support the specificity and potency of the LOX-1 antibody used in the present study.
Discussion
Recent clinical and experimental findings support CRP as a mediator of inflammation and atherogenesis. One of the Figure 5 . Immunofluorescence localization of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and CD32 in coronary arterioles. A, In the presence of anti-endothelial nitric oxide synthase (eNOS, green) or anti-LOX-1 (red) antibody, high levels of immunostaining were detected in endothelial cells (white arrowhead). The merged image shows the overlap staining of eNOS and LOX-1 in arteriolar endothelium (yellow). B, Isolated and pressurized vessels were incubated intraluminally with 7 µg/mL C-reactive protein (CRP) for 60 minutes, followed by addition of anti-CRP (green) or anti-LOX-1 (red) antibody. High levels of immunostaining were detected in endothelial cell layer (white arrowhead). The merged image shows the overlap staining of CRP and LOX-1 in arteriolar endothelium (yellow). C, In the presence of anti-eNOS (green) or anti-CD32 (red) antibody, high levels of immunostaining were detected in endothelial cells (white arrowhead). The merged image shows the overlap staining of eNOS and CD32 (yellow). D, Isolated and pressurized vessels were incubated intraluminally with 7 µg/mL CRP for 60 minutes, followed by addition of anti-CRP (green) or anti-CD32 (red) antibody. High levels of immunostaining were detected in endothelial cell layer (white arrowhead). The merged image shows the overlap staining of CRP and CD32 in arteriolar endothelium (yellow). Scale bar, 50 µm. Data shown are representative of 3 separate experiments. earliest manifestations of atherosclerosis is impairment of endothelial cell function and vascular reactivity. In the current study, we showed that acute exposure of coronary arterioles to CRP, at a concentration known to predict cardiovascular risk, elevated vascular superoxide and led to impaired endothelial function for NO-and PGI 2 -mediated vasodilations through the activation of endothelial LOX-1. By stimulating LOX-1, CRP could contribute to oxidative stressinduced endothelial dysfunction, which is commonly associated with inflammatory cardiovascular diseases. We have also observed a similar inhibitory effect on the endotheliumdependent vasodilation by CRP derived from human serum 36 (Online Figure IV) or by the native form of CRP from ascitic/pleural fluid, 37, 38 further supporting the detrimental actions of CRP with clinical relevance.
Controversial evidence has been reported for the putative CRP receptor in the vascular cells. Earlier reports in cultured human and bovine aortic endothelial cells have indicated that CRP activates CD32, 15, 16, 39 whereas recent studies in the same type of cell lines have shown that CRP can also bind to LOX-1. 18, 19 Although CRP has been shown to increase endothelial expression of both CD32 15, 16 and LOX-1, 19,40 the receptors responsible for the alteration of vasomotor function of intact arterioles by CRP remain unknown. In the current study, we demonstrate for the first time in the intact coronary microvasculature that CRP inhibits endothelium-dependent dilation and promotes superoxide production by activating LOX-1 rather than CD32 because pharmacological blockade of LOX-1 with κ-carrageenan 19 or exposure of the vessels to an anti-LOX-1 antibody, but not to an anti-CD32 antibody, protected the vessels from CRP insult.
LOX-1 exhibits broad ligand specificity by binding to polyanionic compounds, apoptotic cells, and activated platelets, in addition to oxidized low-density lipoprotein. 41 After ligand binding, LOX-1 could mediate a wide array of proatherogenic events, 41 including activation of endothelial NAD(P)H oxidase for superoxide production 42 and reduction of endothelial NO bioavailability through superoxide scavenging. 20 Interestingly, our previous studies showed that the adverse effect of CRP on endothelial NO-mediated dilation and NO production in response to serotonin is also sensitive to the pharmacological blockade of NAD(P)H oxidase. 9 However, it is unclear whether there is a direct link of CRP to LOX-1 activation and the subsequent oxidative stress. In the present study, we demonstrated that CRP markedly increased superoxide levels in small coronary arterioles, which was prevented by the blockade of LOX-1 but not CD32. This CRP-evoked LOX-1-dependent oxidative stress was prevented by endothelial removal (Figure 4 ), suggesting the crucial role of the endothelium in LOX-1 activation and superoxide production. Furthermore, CRP also promotes the generation of peroxynitrite, a product of superoxide and NO interaction, and consequently compromises PGI 2 release and PGI 2 -mediated dilation in response to arachidonic acid. 10 The adverse effect seems to be mediated by the LOX-1 activation because blockade of this receptor effectively preserved vasodilation to arachidonic acid in a manner sensitive to a PGI 2 synthase inhibitor (Figure 3 ). Taking into consideration the broad binding capabilities of LOX-1and the similar properties between CRP 4,9,10 and LOX-1 20, 42 in eliciting endothelial dysfunction, it is likely that CRP interacts with LOX-1 to exert its adverse effect on eNOS- (Figure 2 ) and cyclooxygenase-related ( Figure 3 ) signaling pathways for vasomotor regulation via oxidative insult (Figure 4 ).
LOX-1 is highly expressed in both endothelial cells 43 and smooth muscle cells 41 in large conduit arteries associated with atherosclerotic lesions. However, its expression in normal small resistance vessels has not been documented. In the current study, distinct from previous reports on large conduit vessels, we demonstrated for the first time that LOX-1 is present in the coronary arteriolar wall, primarily in the endothelial layer ( Figure 5 ). This may explain, in part, the evidence that coronary resistance arterioles display little smooth muscle remodeling and anatomic lesions in contrast to their upstream atherosclerotic conduit arteries. 44, 45 CRP was detected in the region heavily expressed with LOX-1 after administration of this peptide. Overlapping of LOX-1 with eNOS expression and coimmunoprecipation of CRP with LOX-1 support the notion that endothelial LOX-1 activation contributed to the rapid adverse effect of CRP on eNOS-mediated vascular regulation. Although we have also shown that CD32 is expressed in the endothelial region of coronary arterioles ( Figure 5 ) and coimmunoprecipitates with CRP ( Figure 6 ), the vasomotor results indicate that CRP/CD32 binding does not contribute to vasodilator dysfunction of arterioles. Our findings suggest that the binding of CRP to LOX-1 is critical for initiating the impairment of endothelium-dependent vasodilation in the intact coronary arterioles. It is noted that although LOX-1 was found primarily in the endothelial layer, superoxide levels were elevated in both the endothelium and smooth muscle after CRP exposure. Because CRP induced negligible DHE signals in the absence of endothelial cells (Figure 4 ), this result supports the idea that increased superoxide production by CRP-LOX-1 interaction is initiated in the endothelium as the primary source. It has been shown that hydrogen peroxide, a downstream product from superoxide dismutase, can impair vasomotor function. 29, 46 Inhibition of hydrogen peroxide formation by cell-permeable polyethylene-glycolated catalase has been reported to prevent hydrogen peroxide signaling in the vasculature. 47 To determine whether hydrogen peroxide contributed to the observed vascular dysfunction in our study, the vessels were pretreated with this modified catalase, and the effect of CRP was subsequently investigated. However, this modified catalase caused loss of basal tone of coronary arterioles, and the vasomotor activity could not be further studied. Nevertheless, using an effective concentration of unmodified catalase, 29, 30 we found that the adverse effect of CRP remained (Online Figure II) , suggesting nominal contribution of hydrogen peroxide in mediating the CRP effect in our preparation.
Under physiological conditions, the endothelial cell release of NO and PGI 2 plays an important role not only in regulating vascular tone, but also in maintaining an antithrombogenic layer. Both NO and PGI 2 can increase local tissue perfusion and maintain microvascular homeostasis by eliciting vasodilation and inhibiting platelet and inflammatory cell adherence to the vessel wall. The endothelium can also influence vessel patency by producing fibrinolytic system factors including tissue plasminogen activator and its inhibitor PAI-1. 48 PAI-1 inhibits tissue plasminogen activator, which is the primary serine protease that converts plasminogen to plasmin resulting in degradation of platelet-fibrin thrombi. Because elevated plasma levels of PAI-1 are associated with coronary artery disease, 49, 50 CRP may have a direct effect on the fibrinolytic system as suggested by the evidence of downregulation of tissue plasminogen activator 51 and upregulation of PAI-1 by CRP stimulation in cultured endothelial cells. 35, [52] [53] [54] [55] [56] These molecular findings may explain the observed enhancement of thrombosis in CRP transgenic mice with arterial injury 57 and the promotion of inflammation and coagulation in parallel with PAI-1 elevation in response to intravenous infusion of CRP in healthy human subjects. 58 However, the receptors contributing to the CRP effect remain to be determined. Furthermore, although CRP has been implicated to regulate PAI-1 levels via CD32 activation in HCAEC, 35 its effect on the expression of PAI-1 in intact blood vessels remains unknown. In the present study, we found that PAI-1 protein expression in coronary arterioles was significantly increased after a 12-hour incubation with CRP. Interestingly, either LOX-1 or CD32 blockade abolished the CRP-induced increase in vascular PAI-1 expression (Figure 7 ), suggesting a close link, possibly via transactivation of receptor signaling cascades, of both LOX-1 and CD32 in PAI-1 regulation in coronary arterioles. However, we found that CD32 activation was requisite for CRP-induced PAI-1 expression in HCAEC (Figure 8 ), in agreement with a previous report. 35 Although the ability of LOX-1 to increase PAI-1 expression by oxidized low-density lipoprotein has been recently shown in the same cell type, 59 we found that LOX-1 blockade failed to prevent PAI-1 upregulation by CRP ( Figure 8 ). The explanation for the observed inconsistency in LOX-1-and CD32-dependent induction of PAI-1 by CRP in intact vessels versus HCAEC in the present study remains unclear. It is possible that the heterogeneity in signaling for PAI-1 regulation may exist in macrovascular (cultured HCAEC from large conduit arteries) versus microvascular (intact coronary arterioles) endothelium because this phenomenon has been widely reported [60] [61] [62] and may contribute to the functional heterogeneity of endothelial PAI-1 activity in the heart. 63 Because vascular smooth muscle cells also have been shown to produce PAI-1, 64, 65 our results may imply that the CRP binding of LOX-1 to cause PAI-1 induction is through a nonendothelial pathway in coronary arterioles, assuming that arteriolar endothelial cells behave the same as HCAEC. It is also likely that the induction and activation of LOX-1 in the smooth muscle might have occurred after a long-term exposure of coronary arterioles to abluminal CRP for 12 hours and contributed to the enhanced PAI-1 expression. It is worth noting that a conformational change of CRP from the native pentamer to a monomer form has been shown to alter its bioactivity and receptor binding 66, 67 and thus may contribute to our disparate results in arterioles versus HCAEC. However, it has been shown that only native CRP binds to CD32 and LOX-1. 15, 18, 27, 68 In the present study, the pentameric CRP was used as verified by native gel electrophoresis under nonreducing conditions 36 (Online Figure V) . Our findings provide new evidence that CRP selectively activates LOX-1 in the microvasculature to exert an adverse effect on endothelium-dependent vasomotor function but upregulates prothrombogenic protein PAI-1 via combined LOX-1/CD32 activation.
In summary, the present study demonstrates the novel finding that porcine coronary arterioles display functional LOX-1 and CD32 and that CRP elicits vasodilator dysfunction via selective activation of endothelial LOX-1. Furthermore, CRP can increase the arteriolar expression of PAI-1 after activation of these receptors. It seems that activation of both LOX-1 and CD32 by CRP in arterioles may contribute to vascular dysfunction and promote a thrombotic milieu by reducing protective endothelial factors (NO and PGI 2 ) and upregulating thrombogenic factor PAI-1. The abundant expression of LOX-1 and CD32 in the endothelium of coronary resistance vessels may participate in the dysregulation of coronary flow and myocardial ischemia in patients with cardiac syndrome X, corresponding to elevated CRP levels and impaired endothelium-dependent vasodilator function 69 (see Editorial). 70
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